Bioventix (BVXP) is a small company that has recently listed on AIM. To quote from the company's web site: " Bioventix is a biotechnology company specialising in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The high-affinity antibodies created at Bioventix have advantages over conventional rodent monoclonal antibodies where the target is present at low concentration, or where the target is a hapten or small molecule. The use of high-affinity SMAs also confers improved assay sensitivity and precision. Bioventix has successfully developed SMAs to targets where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent ". Revenue in the last financial year was £3.5m and post-tax profits were £1.8m, even after
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.